MX2020010144A - Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38). - Google Patents
Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38).Info
- Publication number
- MX2020010144A MX2020010144A MX2020010144A MX2020010144A MX2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A MX 2020010144 A MX2020010144 A MX 2020010144A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- subcutaneous dosing
- disclosed
- methods
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen métodos para administrar anticuerpos anti-CD38 aislados por vía subcutánea. Los métodos proporcionan un tratamiento eficaz para las enfermedades autoinmunes y los cánceres, incluidas las enfermedades hematológicas. También se describen formas de dosificación unitaria para los anticuerpos anti-CD38.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862649489P | 2018-03-28 | 2018-03-28 | |
PCT/IB2019/000314 WO2019186273A1 (en) | 2018-03-28 | 2019-03-27 | Subcutaneous dosing of anti-cd38 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020010144A true MX2020010144A (es) | 2020-12-07 |
Family
ID=66647425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010144A MX2020010144A (es) | 2018-03-28 | 2019-03-27 | Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38). |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210047427A1 (es) |
EP (1) | EP3774915A1 (es) |
JP (2) | JP2021519295A (es) |
KR (1) | KR20210002499A (es) |
CN (1) | CN112154156A (es) |
AU (1) | AU2019244478A1 (es) |
BR (1) | BR112020019710A2 (es) |
CA (1) | CA3095086A1 (es) |
CO (1) | CO2020013252A2 (es) |
MX (1) | MX2020010144A (es) |
TW (1) | TW202003566A (es) |
WO (1) | WO2019186273A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
CA2969717A1 (en) | 2014-12-04 | 2016-06-09 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
RS63210B1 (sr) | 2015-11-03 | 2022-06-30 | Janssen Biotech Inc | Potkožne formulacije anti-cd38 antitela i njihova upotreba |
JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク,インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
JP2021536254A (ja) * | 2018-09-11 | 2021-12-27 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co., Ltd. | 抗cd38抗体、その抗原結合フラグメント、および医薬用途 |
CN113195540A (zh) * | 2018-10-17 | 2021-07-30 | 詹森生物科技公司 | 提供皮下施用抗cd38抗体的方法 |
BR112022023137A2 (pt) * | 2020-05-15 | 2023-02-07 | Takeda Pharmaceuticals Co | Administração de inibidor de enzima de ativação de sumo e anticorpos anti-cd38 |
EP4376869A1 (en) | 2021-07-28 | 2024-06-05 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
WO2023045859A1 (zh) * | 2021-09-23 | 2023-03-30 | 非同(成都)生物科技有限公司 | Cd38单克隆抗体及其应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
IT1320715B1 (it) | 2000-10-19 | 2003-12-10 | Cselt Centro Studi Lab Telecom | Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e |
CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
WO2003011161A1 (en) | 2001-08-03 | 2003-02-13 | Tyco Healthcare Group Lp | Tissue marking apparatus and method |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
EP2551282A3 (en) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
AR053489A1 (es) | 2005-05-24 | 2007-05-09 | Morphosys Ag | Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano |
WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
MA44560B2 (fr) * | 2014-07-31 | 2021-01-29 | Sanofi Sa | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
HUE054271T2 (hu) * | 2015-05-13 | 2021-08-30 | Morphosys Ag | Mielóma Multiplex (MM) kezelése |
RS63210B1 (sr) * | 2015-11-03 | 2022-06-30 | Janssen Biotech Inc | Potkožne formulacije anti-cd38 antitela i njihova upotreba |
WO2018013917A1 (en) * | 2016-07-15 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
-
2019
- 2019-03-27 AU AU2019244478A patent/AU2019244478A1/en active Pending
- 2019-03-27 BR BR112020019710-6A patent/BR112020019710A2/pt unknown
- 2019-03-27 CN CN201980032101.8A patent/CN112154156A/zh active Pending
- 2019-03-27 MX MX2020010144A patent/MX2020010144A/es unknown
- 2019-03-27 JP JP2020551797A patent/JP2021519295A/ja active Pending
- 2019-03-27 EP EP19726474.0A patent/EP3774915A1/en active Pending
- 2019-03-27 US US17/041,783 patent/US20210047427A1/en active Pending
- 2019-03-27 WO PCT/IB2019/000314 patent/WO2019186273A1/en unknown
- 2019-03-27 CA CA3095086A patent/CA3095086A1/en active Pending
- 2019-03-27 KR KR1020207030604A patent/KR20210002499A/ko unknown
- 2019-03-28 TW TW108110990A patent/TW202003566A/zh unknown
-
2020
- 2020-10-22 CO CONC2020/0013252A patent/CO2020013252A2/es unknown
-
2023
- 2023-12-25 JP JP2023218600A patent/JP2024045121A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3095086A1 (en) | 2019-10-03 |
US20210047427A1 (en) | 2021-02-18 |
TW202003566A (zh) | 2020-01-16 |
AU2019244478A1 (en) | 2020-11-12 |
BR112020019710A2 (pt) | 2021-01-26 |
RU2020135062A3 (es) | 2022-04-28 |
JP2024045121A (ja) | 2024-04-02 |
CO2020013252A2 (es) | 2020-11-10 |
RU2020135062A (ru) | 2022-04-28 |
JP2021519295A (ja) | 2021-08-10 |
EP3774915A1 (en) | 2021-02-17 |
WO2019186273A4 (en) | 2019-12-19 |
CN112154156A (zh) | 2020-12-29 |
WO2019186273A1 (en) | 2019-10-03 |
KR20210002499A (ko) | 2021-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020010144A (es) | Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38). | |
MX2020010458A (es) | Conjugados de camptotecina-peptido. | |
MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
MX2019012462A (es) | Terapia combinada. | |
PH12020550805A1 (en) | Exosomes for immuno-oncology and anti-inflammatory therapy | |
MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
MX2021002764A (es) | Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores. | |
MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
MX2016013863A (es) | Combinacion de lenalidomida y constructo de polipeptido, y sus usos. | |
MX2019011148A (es) | Metodos de tratamiento. | |
TN2018000021A1 (en) | ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY. | |
MX2017014977A (es) | Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2. | |
MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
MX2022003306A (es) | Inmunocitoquina que comprende un complejo de proteina heterodimerico basado en il-15/il-15ra y su uso. | |
MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
MX2020007429A (es) | Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). | |
MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
MX2023008849A (es) | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. | |
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
MX2021010313A (es) | Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38. | |
MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
EA201992852A1 (ru) | Схема дозирования тезетаксела и капецитабина | |
WO2020086479A9 (en) | Dosing |